Biogen Is A Frustrating Case, And Piper Jaffray Hopes It Doesn't Regret Upgrade
November 07, 2016 at 08:58 AM EST
The current valuation of Biogen Inc’s (NASDAQ: BIIB) stock represents “a reasonable entry for the Alzheimer's and SMA ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.